市场见解

Own CSL shares? Here’s what’s in the development pipeline

Research into messenger RNA (mRNA) has ramped up since the onset of COVID-19.
The post Own CSL shares? Here’s what’s in the development pipeline appeared first on The Motley Fool Australia. –

CSL Ltd (ASX: CSL) shares have gained 7% since the S&P/ASX 200 Index (ASX: XJO) listed biotech share held its annual research and development (R&D) briefing on 19 October.

Below, we take a look at what’s in that pipeline.

What is the ASX 200 biotech company developing?

As the Motley Fool reported on the day, CSL invested more than US$1 billion (AU$1.35 billion) into R&D in the 2021 financial year. That money supported 6 therapeutic areas, 4 scientific platforms, and 2 businesses.

Breaking those down, the 6 therapeutic areas are:

Immunology,
Hematology,
Respiratory,
Cardiovascular and metabolic,
Transplant, and
Influenza

The 4 scientific platforms are:

Plasma fractionation,
Recombinant technology,
Cell and gene therapy, and
Vaccines

And the 2 businesses are:

CSL Behring, and
Seqirus

Among the highlights, CSL announced that its Seqirus business was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services.

The multi-year contract centres around CSL’s adjuvanted, cell-based seasonal influenza vaccine (aQIVc) and next-generation self-amplifying mRNA for seasonal and pandemic influenza (sa-mRNA). CSL intends to develop 2 influenza A(H2Nx) vaccine candidates for assessment in a Phase 1 clinical study. The end goal is to help communities stay safe in the event of an influenza pandemic.

CSL also announced a new collaboration with the Walter and Eliza Hall Institute for Medical Research in Australia to create a Centre for Biologic Therapies.

Commenting on that collaboration and what it means for CSL’s development pipeline, CSL’s Senior Vice President Andrew Nash said:

CSL’s antibody library will be the engine room of biologics discovery at the Centre and, importantly, the knowledge transfer between the two organizations and the utilization of shared assets, resources, and facilities will be of great value.

This expansion of our relationship with WEHI will help ensure that the long-term investment of public funds into medical research in Australia is translated into both a benefit for patients and the Australian economy.

How have CSL shares been performing?

CSL shares have been on a bit of a rollercoaster over the past 12 months. It’s a ride that has left them 3% in the green. By comparison, the ASX 200 has gained 17% over the same period.

Over the past month, CSL shares are up 8%.

The post Own CSL shares? Here’s what’s in the development pipeline appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

The CSL (ASX:CSL) share price is now well above $300. Is it on a roll?

2 buy-rated blue chip ASX shares to boost your portfolio

What happened to the CSL (ASX:CSL) share price in October?

Own biotech shares? These were the best performers during October

CSL (ASX:CSL) share price lifts 2% amid US border patrol battle

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!